Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board

PRINCETON, N.J., and PARIS, June 20, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that Gilles Montalescot, M.D., PhD, has joined its Scientific Advisory Board (SAB).

Prof. Montalescot heads the Cardiac Care Unit at Pitié-Salpêtrière Hospital in Paris and has been principal investigator of several national or international randomized trials, especially in the field of Acute Coronary Syndrome. Dr Montalescot has received several awards including the J. Valade Prize from the Fondation de France and the J. Escalle award from the French National Academy of Medicine. He is a member of the editorial board of the European Heart Journal and has published many peer-reviewed articles in journals such as the New England Journal of Medicine, JAMA or Circulation.

“I am delighted to become an advisor to STENTYS clinical and scientific strategy,” said Prof. Montalescot. “In cases of STEMI heart attacks, vasoconstrictive forces make true vessel-size difficult to assess and interventional cardiologists must struggle with this dilemma on a daily basis. STENTYS self-apposing technology is a radical improvement over conventional stents as it solves the dilemma of stent sizing, which should translate into better results for the patients.”

The STENTYS stent represents a major breakthrough when treating heart attacks: it is self-apposing, i.e. it “fits snugly” into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: malapposition.

About STENTYS
Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its self-apposing stent adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

# # # # #